Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...
Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...
BMS is a block model time simulator: it computes time values of time functions (called variables) linked by blocks which represent equations and behaviors between them. A model (class DynamicSystem) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback